false
0001583771
0001583771
2026-08-19
2026-08-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 19, 2026
Hepion
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-36856 |
|
46-2783806 |
| (State
or other jurisdiction of incorporation or organization) |
|
(Commission
File
Number) |
|
(IRS
Identification No.) |
34
Shrewsbury Ave., Suite 1C
Red
Bank, NJ 07701
(Address
of principal executive offices)
(732)
902-4000
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title of each class: |
|
Trading Symbol(s) |
|
Name of each exchange on which registered: |
| Common
Stock, par value $0.0001 per share |
|
HEPA |
|
OTC
QB |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure
of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
On
August 19, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) approved the appointment of James
Liddy as a director of the Company, effective immediately.
There
are no arrangements or understandings between the new director and any other person pursuant to which he was selected as a director,
and there are no transactions involving the Company and the new director that the Company would be required to report pursuant to Item
404(a) of Regulation S-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
August 20, 2026 |
Hepion Pharmaceuticals, Inc. |
| |
|
|
| |
By: |
/s/
Gary Stetz |
| |
|
Gary
Stetz |
| |
|
Interim
Chief Executive Officer |
